Video recap of ILC 2018 final day
In this issue: The Sunday edition of the ILC 2018 daily news draws the congress to a close after another packed day of scientific symposia, breakfast rounds, updates on Clinical Practice Guidelines, and meet the expert sessions…. Scroll down to read more!
ILC 2018 final day!
The well-attended breakfast morning rounds covered practical aspects of hepatology with discussions around a series of case studies on the difficult-to-treat patient with chronic hepatitis C, how to diagnose and treat DILI, strictures of the bile duct, and diagnosis and work up on a cirrhotic patient with a single nodule. Delegates also had another opportunity to meet face-to-face with experts to discuss the management of hepatitis D and Wilson’s disease.
Other key highlights in today’s news:
- An exciting collaboration with ESMO to help advance treatment of liver cancer
- A rundown on the best posters of ILC 2018
- Diagnostic dilemmas in metabolic liver disease
- Guidelines updates on HEV, DILI and ALD
EASL would like to thank all faculty, presenters and attendees for their participation and contributions to yet another hugely successful ILC.
Safe journey home and see you Vienna in 2019!
The best of the best at ILC 2018
During the packed wrap-up session, four eminent hepatologists, Drs Maria Buti, Herbert Tilg, Fabio Piscaglia and Dominique Thabut, gave an overview of their choices of best of the best in clinical and basic research at ILC 2018 in the fields of viral hepatitis, metabolic and cholestatic diseases, HCC, and complications of cirrhosis and liver transplantation.
The best posters presented at this year’s ICL were showcased, selected by key opinion leaders in each of the main hepatology topics, viral hepatitis (Christophe Hézode), metabolic and cholestasis (Lawrence Serfaty), hepatocellular carcinoma (Jens Marquardt), and general hepatology including liver transplantation (Agustín Albillos). They all commented on the particularly high quality of the research and global reach. The best poster selection covered all aspects of liver cancer, from epidemiology and basic science, to the latest developments in biomarkers and clinical therapies. Don’t forget that all ePosters are available on LiverTree.
Three new EASL CPGs released
It was with great interest that the first ever EASL Clinical Practice Guidelines on HEV infection were presented today by guideline panel chair, Dr Harry Dalton. HEV is endemic in most high-income countries and now the commonest cause of acute viral hepatitis in Europe; it represents an important global public health problem, causing significant morbidity and mortality. The new guidelines focus on HEV GT 3 and 4 and recommend that whereas most HEV infection clears spontaneously, patients with chronic liver failure or who are immunosuppressed may need antiviral ribavirin treatment, but extrahepatic neurological manifestations of HEV are particulary hard to treat. Dr Dalton noted that the EASL CPG should be considered alongside the WHO guidelines for the management of outbreaks of acute HEV in resource-limited settings.
The long-awaited EASL CPG guidelines on DILI were presented by Prof. Raúl J. Andrade who gave a comprehensive overview of the recommendations, including diagnostics and classification of liver injury, genetic testing, treatment and management, prevention of DILI, and management of special phenotypes. Unmet needs in the management of DILI were also discussed, including the need for better predictive biomarkers and randomized controlled trials to evaluate specific interventions on clinical outcomes.
ILC attendees appreciated the guidance provided in the multidisciplinary, and often complex, management of patients with ALD. Prof. Mark Thursz disseminated EASL’s newly published Clinical Practice Guidelines on Management of Alcohol-Related Liver Disease, providing up to date recommendations for clinical management. The need for multi-disciplinary care was highlighted once again, to effectively manage a patient population who often have multiple comorbidities.
Summary slide decks of EASL CPGs are available on the ILC website.
Aggressive management of stage 3 AKI in cirrhosis required
Updated data on the significant burden of impaired renal function in cirrhosis and new insights on the mechanisms involved were discussed on Sunday morning. Data were presented on novel renal biomarkers that may help identify patients with a potential for renal recovery after liver transplant. The management of patients with advanced cirrhosis and stage 3 AKI remains very heterogeneous and there was a call to action for a consensus on its aggressive management.
EASL and ESMO collaborate
In a symposium co-organized with the European Society for Medical Oncology (ESMO), medical oncologists and hepatologists met to discuss the advantages of a multidisciplinary team (MDT) approach to treating patients with liver cancer, including use of the latest advances in personalized medicines. Multidisciplinary management of HCC requires a continuum of expertise that encompasses medical oncology, hepatology and surgery to optimize treatment of this unique disease, with a concerted effort at an institutional level to encourage the integration of MDTs. With the development of several therapies to treat HCC, we also need a better understanding of the underlying pathology of different HCC tumour types in order to transition to more personalized treatment strategies.
ILCA 2018, an interdisciplinary meeting bringing together oncologists, hepatologists and cancer surgeons, will take place in London, 14–16 September.
It's not over!
You can still engage with ILC 2018 when you get home:
- The ePosters and webcasts are available on Liver Tree™ now and after the meeting
- Obtain your CME credits
Available or coming soon online:
The ILC daily news was supported by grants from: Abbvie, Alexion, Boehringer Ingelheim, Gilead, Janssen, MSD and Pfizer.